Compare Global X Lithium & Battery Tech ETF (LIT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.7× Global X Lithium & Battery Tech ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LIT | ZBH | |
|---|---|---|
Market Cap | $1.45B | $16.95B |
Volume | 89,392 | 2,505,240 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $103.98 |
52-Week Low | $53.92 | $79.58 |
Typical Hold Time | 56 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.02, down 0.7% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's recent performance reflects ongoing volatility in lithium markets, with short interest dropping 53.1% in September 2026. Recent news highlights continued growth in electric vehicle adoption and China's ambitious 30% NEV fleet target by 2030, supporting long-term battery technology demand.
The ETF presents exposure to the growing battery technology sector with strong catalysts from EV adoption and energy storage markets. However, investors face risks from lithium price volatility, Chinese export controls on critical minerals, and geopolitical trade tensions that could impact supply chains and performance.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
